Stem cells for the heart, are we there yet?

被引:14
|
作者
Timmermans, F [1 ]
De Sutter, J [1 ]
Gillebert, TC [1 ]
机构
[1] Univ Ghent, Dept Cardiovasc Dis, B-9000 Ghent, Belgium
关键词
stem cells; myocardial infarction; delivery; differentiation; adverse effects;
D O I
10.1159/000074811
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Although several repair mechanisms have been described in the human heart, all fall too short to prevent clinical heart disease in most acute or chronic pathological cardiac conditions. Moreover, despite many breakthroughs in cardiovascular medicine, the complications of a myocardial infarction such as chronic heart failure remains a serious worldwide problem. Bone marrow stem cells could provide for a promising strategy to restore myocardial infarctions and prevent postinfarct congestive heart failure, because there is growing body of evidence that bone marrow stem cells, such as mesenchymal stem cells, can generate new cardiomyocytes in animals and humans. In this review, we will discuss important issues on stem cell therapy for cardiac regeneration after myocardial infarction, which might be of paramount importance when considering future human trials. Copyright (C) 2003 S. Karger AG, Basel.
引用
收藏
页码:176 / 185
页数:10
相关论文
共 50 条
  • [31] Targeting Myocardial Energetics in the Failing Heart Are We There Yet?
    Mann, Douglas L.
    CIRCULATION-HEART FAILURE, 2017, 10 (12)
  • [32] Use of biomarkers in the management of heart failure - Are we there yet?
    Bozkurt, B
    Mann, DL
    CIRCULATION, 2003, 107 (09) : 1231 - 1233
  • [33] Echo Screening for Rheumatic Heart Disease Are We There Yet?
    Longenecker, Chris T.
    CIRCULATION-CARDIOVASCULAR IMAGING, 2019, 12 (02)
  • [34] Editorial commentary: Management of heart failure: Are we there yet?
    Zhang, David
    Dandamudi, Gopi
    TRENDS IN CARDIOVASCULAR MEDICINE, 2020, 30 (08) : 519 - 520
  • [35] Human embryonic stem cells for heart repair: where are we now?
    Puceat, Michel
    Jaconi, Marisa E.
    CURRENT OPINION IN ORGAN TRANSPLANTATION, 2007, 12 (06) : 647 - 651
  • [36] Progress in the Tissue Engineering and Stem Cell Industry "Are we there yet?"
    Jaklenec, Ana
    Stamp, Andrea
    Deweerd, Elizabeth
    Sherwin, Angela
    Langer, Robert
    TISSUE ENGINEERING PART B-REVIEWS, 2012, 18 (03) : 155 - 166
  • [37] Stem-cell therapy for hearing loss: are we there yet?
    Dufner-Almeida, Luiz Gustavo
    da Cruz, Dayane Bernardino
    Mingroni Netto, Regina Celia
    Batissoco, Ana Carla
    Oiticica, Jeanne
    Salazar-Silva, Rodrigo
    BRAZILIAN JOURNAL OF OTORHINOLARYNGOLOGY, 2019, 85 (04) : 520 - 529
  • [38] Stem cell therapies for neonatal lung diseases: Are we there yet?
    Thebaud, Bernard
    SEMINARS IN PERINATOLOGY, 2023, 47 (03)
  • [39] Towards a Functional Cure for Diabetes Using Stem Cell-Derived Beta Cells: Are We There Yet?
    Bourgeois, Stephanie
    Sawatani, Toshiaki
    Van Mulders, Annelore
    De Leu, Nico
    Heremans, Yves
    Heimberg, Harry
    Cnop, Miriam
    Staels, Willem
    CELLS, 2021, 10 (01) : 1 - 24
  • [40] Yet another role for mesenchmyal stem cells?
    Newsome, Philip
    TRANSPLANTATION, 2008, 85 (11) : 1548 - 1549